Ligand Pharmaceuticals Director Unloads: Investor Guide
A director sold a chunk of Ligand Pharmaceuticals stock, prompting questions about intent and impact. This guide brea...
Saving money doesn't have to be dull! Explore creative ways to keep your savings journey enjoyable and engaging.
28,655 articlesA director sold a chunk of Ligand Pharmaceuticals stock, prompting questions about intent and impact. This guide brea...
Intel is resetting expectations around AI with a focus on edge infrastructure and domestic manufacturing, signaling a...
When a company director buys a sizable stake, investors take notice. This article breaks down the meaning behind the ...
Oil shocks tied to the Iran conflict threaten U.S. growth as prices rise. Analysts say a price threshold around $110 ...
Solstice and TensorX unveil a financing pact to fund up to $1 billion in European sovereign AI infrastructure, using ...
Raymond James raises Marathon's target to 270, driven by sustained refining margins and strong MPLX distributions. MP...
New disclosures reveal a mixed picture: five Fortune 500 holdings drew public commentary in 2026, while two media nam...
Iran publicly spurns ceasefire talks amid renewed attacks, while the White House insists talks continue. The flare-up...
As workers reassess early retirement, a dividend-heavy portfolio could substitute lost full-time income. This piece b...
A harsh winter trimmed fishing days and boosted costs for Maine’s lobster sector, even as 2025 revenue stayed above $...
NVIDIA’s latest results highlight a powerful software moat and growing AI infrastructure demand, underscoring why man...
A political shift in the United States is denting confidence in mRNA medicine, with funding drying up and manufacturi...